The beneficial effects of levetiracetam on polyneuropathy in the early stage of sepsis in rats: Electrophysiological and biochemical evidence

Journal of Investigative Surgery

Volumn 26, Issue 6, 2013, Pages 312-318

  Erbaş, Oytun ^a   Yeniel, A Özgür ^a   Akdemir, Ali ^a   Ergenoǧlu, A Mete ^a   Yilmaz, Mustafa ^b   Taskiran, Dilek ^a   Peker, Gönül ^a  

^a EGE UNIVERSITY   (Turkey)

^b MUGLA SITKI KOCMAN UNIVERSITY   (Turkey)

Author keywords

Compound muscle action potentials (CMAPs); Critical illness polyneuropathy; Electromyography; Levetiracetam; Sepsis

Indexed keywords

ANTIOXIDANT; ETIRACETAM; LIPID PEROXIDE; MALONALDEHYDE; MYELIN; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; CECUM; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ELECTROMYOGRAM; ELECTROPHYSIOLOGY; MALE; MUSCLE ACTION POTENTIAL; NERVE FIBER; NONHUMAN; PERIPHERAL NERVE; POLYNEUROPATHY; PRIORITY JOURNAL; RAT; SEPSIS;

ACTION POTENTIALS; ANIMALS; ANTIOXIDANTS; ELECTROMYOGRAPHY; MALE; MALONDIALDEHYDE; MUSCLES; PIRACETAM; POLYNEUROPATHIES; RATS; RATS, SPRAGUE-DAWLEY; SEPSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84887948271     PISSN: 08941939     EISSN: 15210553     Source Type: Journal    
DOI: 10.3109/08941939.2013.797056     Document Type: Article

References (37)

1. Bolton CF, Gilbert JJ, Hahn AF, et al. Polyneuropathy in critically ill patients. J Neurol Neurosurg Psychiatry. 1984;47:1223-1231
2. Bolton CF. Neuromuscularmanifestations of critical illness. Muscle Nerve. 2005;32:140-163
3. Stevens RD, Dowdy DW, Michaels RK, et al. Neuromuscular dysfunction acquired in critical illness: A systematic review. Intensive Care Med. 2007;33:1876-1891
4. Pati S, Goodfellow JA, Iyadurai S, et al. Approach to critical illness polyneuropathy and myopathy. Postgrad Med J. 2008;84:354-360
5. Hermans G, De Jonghe B, Bruyninckx F, et al. Clinical review: Critical illness polyneuropathy and myopathy. Crit Care. 2008;12:238
6. Tennila A, Salmi T, Pettila V, et al. Early signs of critical illness polyneuropathy in ICU patients with systemic inflammatory response syndrome or sepsis. Intensive Care Med. 2000;26:1360-1363
7. Guillouet M, Gueret G, Rannou F, et al. Tumor necrosis factor-α downregulates sodium current in skeletal muscle by protein kinase C activation: Involvement in critical illness polyneuromyopathy. Am J Physiol Cell Physiol. 2011;301:C1057-C1063
8. Chawla J, Gruener G. Management of critical illness polyneuropathy and myopathy. Neurol Clin. 2010;28:961-977
9. Cankayali I, Dogan HY, Solak I, et al. Effects of IgM enriched immunoglobulin and fluid replacement on nerve conduction velocity in experimental sepsis. Ulus Travma Acil Cerrahi Derg. 2010;16:9-14
10. Atis S, Nayci A, Ozge A, et al. N-acetylcysteine protects the rats against phrenic nerve dysfunction in sepsis. Shock. 2006;25:30-35
11. Ortolani O, Conti A, De Gaudio AR, et al. The effect of glutathione and N-acetylcysteine on lipoperoxidative damage in patients with early septic shock. Am J Respir Crit Care Med. 2000;161:1907-1911
12. Berger MM, Chioĺero RL. Antioxidant supplementation in sepsis and systemic inflammatory response syndrome. Crit Care Med. 2007;35:S584-S590
13. Lukyanetz EA, Shkryl VM, Kostyuk PG. Selective blockade of N-type calcium channels by levetiracetam. Epilepsia. 2002;43:9-18
14. Poulain P, Margineanu DG. Levetiracetam opposes the action of GABAA antagonists in hypothalamic neurons. Neuropharmacology. 2002;42:346-352
15. Madeja M, Margineanu DG, Gorji A, et al. Reduction of voltage-operated potassium currents by levetiracetam: A novel antiepileptic mechanism of action Neuropharmacology. 2003;45:661-671
16. Lynch BA, Lambeng N, Nocka K, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA 2004;101:9861-9866
17. Costa C, Martella G, Picconi B, et al. Multiple mechanisms underlying the neuroprotective effects of antiepileptic drugs against in vitro ischemia. Stroke. 2006;37:1319-1326
18. Hanon E, Klitgaard H. Neuroprotective properties of the novel antiepileptic drug levetiracetam in the rat middle cerebral artery occlusion model of focal cerebral ischemia. Seizure. 2001;10:287-293
19. Marini H, Costa C, Passaniti M, et al. Levetiracetam protects against kainic acid-induced toxicity. Life Sci. 2004;74:1253-1264
20. Belcastro V, Pierguidi L, Tambasco N. Levetiracetam in brain ischemia: Clinical implications in neuroprotection and prevention of post-stroke epilepsy. Brain Dev. 2011;33:289-293
21. Wichterman KA, Baue AE, Chaudry IH. Sepsis and septic shock - a review of laboratory models and a proposal. J Surg Res. 1980;29:189-201
22. Demougeot C, Marie C, Beley A. Importance of iron location in iron-induced hydroxyl radical production by brain slices. Life Sci. 2000;67:399-410
23. Benzie IF, Strain JJ. Ferric reducing/antioxidant power assay: Direct measure of total antioxidant activity of biological fluids and modified version for simultaneousmeasurement of total antioxidant power and ascorbic acid concentration. Methods Enzymol. 1999;299:15-27
24. Bernal ME, Varon J, Acosta P, et al. Oxidative stress in critical care medicine. Int J Clin Pract. 2010;64:1480-1488
25. Trojaborg W, Weimer LH, Hays AP. Electrophysiologic studies in critical illness associated weakness: Myopathy or neuropathy - a reappraisal. Clin Neurophysiol. 2001;112:1586-1593
26. Nayci A, Atis S, Comelekoglu U, et al. Sepsis induces early phrenic nerve neuropathy in rats. Eur Respir J. 2005;26:686-692
27. Cankayali I, Dogan YH, Solak I, et al. Neuromuscular deterioration in the early stage of sepsis in rats. Crit Care. 2007; 11:R1
28. Novak KR, Nardelli P, Cope TC, et al. Inactivation of sodium channels underlies reversible neuropathy during critical illness in rats. J Clin Invest. 2009;119:1150-1158
29. Oliveira AA, Almeida JP, Freitas RM, et al. Effects of levetiracetam in lipid peroxidation level, nitrite-nitrate formation and antioxidant enzymatic activity in mice brain after pilocarpine-induced seizures. Cell Mol Neurobiol. 2007;27:395-406
30. Zapater P, Moreno J, Horga JF. Neuroprotection by the novel calcium antagonist PCA50938, nimodipine and flunarizine, in gerbil global brain ischemia. Brain Res. 1997;772:57- 62
31. Lo AC, Black JA, Waxman SG. Neuroprotection of axons with phenytoin in experimental allergic encephalomyelitis. Neuroreport. 2002;13:1909-1912
32. Stettner M, Dehmel T, Mausberg AK, et al. Levetiracetam exhibits protective properties on rat Schwann cells in vitro. J Peripher Nerv Syst. 2011;16:250-260
33. Dubovy P. Wallerian degeneration and peripheral nerve conditions for both axonal regeneration and neuropathic pain induction. Ann Anat. 2011;193:267-275
34. Zindler E, Zipp F. Neuronal injury in chronic CNS inflammation. Best Pract Res Clin Anaesthesiol. 2010;24:551-562
35. Fang C, Bourdette D, Banker G. Oxidative stress inhibits axonal transport: Implications for neurodegenerative diseases. Mol Neurodegener. 2012;7:29
36. Vogl C, Mochida S,Wolff C, et al. The synaptic vesicle glycoprotein 2A ligand levetiracetam inhibits presynaptic Ca2+ channels through an intracellular pathway. Mol Pharmacol. 2012;82:199-208
37. Fei G, Guo C, Sun HS, et al. Chronic hypoxia stressinduced differential modulation of heath-shock protein 70 and presynaptic proteins. J Neurochem. 2007; 100: 50-61